Use of catechin for preventing or treaitng coronary restenosts

A technology of catechins and restenosis, applied in the field of catechins, can solve problems such as limited efficacy

Inactive Publication Date: 2002-08-07
SAM A PHARMA CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these methods are limited in their effectiveness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of catechin for preventing or treaitng coronary restenosts
  • Use of catechin for preventing or treaitng coronary restenosts
  • Use of catechin for preventing or treaitng coronary restenosts

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0031] Also, unless otherwise specified, the following percentages of solids in solid mixtures, liquids in liquid mixtures, and solids in liquids are given in wt / wt, vol / vol and wt / vol, respectively. Reference Example 1: Preparation of GTC

example 2

[0032] First, 1000 g of green tea (Theae sinensis L., Theaceae-var. bohea (yabugida), Geju-do of Republic of Korea) was extracted with 10 liters of 70% ethanol at about 87°C for 3 hours, and then extracted with 5 liters of the same solvent . The combined extracts were concentrated to a volume of 1 L using a vacuum rotary dryer. To the concentrate was added 2 liters of water, followed by centrifugation at 14,000 rpm for 20 minutes to separate solid matter. The supernatant was washed with 1.2 times the volume of chloroform, and the aqueous layer was extracted 4 times with 1.2 times the volume of ethyl acetate each time. The ethyl acetate fractions were combined and the solvent was evaporated under reduced pressure. The residue was dissolved in a small amount of water and lyophilized to obtain GTC powder. Reference Example 2: Quantitative Analysis of GTC

[0033] (1) Quantitative analysis of all catechin contents in GTC

[0034] To 25 mg of the GTC powder obtained in Referen...

example 3

[0051] It is thus found that based on the total amount of catechins, GTC powder contains 37.5% (w / w) EGCG, 12.5% ​​(w / w) EGC, 5.7% (w / w) ECG, and the balance is other Catechins. Reference Example 3: Primary culture of rat VSMCs

[0052] 7-week-old Sprague-Dawley male rats (Korean Experimental Animal Center Ltd.) and 12-14-week-old Fisher 344 male rats (Charles River, Japan) were used in the experiments. with CO 2 Each rat was asphyxiated, its chest cavity was sterilized and opened to remove the aorta. All surgical instruments and glassware are autoclaved, and all operations are performed on a clean operating table. The aorta was immersed in physiological saline solution (PSS), and its adipose tissue was removed. The resulting aorta was treated with 0.2% collagenase for 30 minutes in an incubator maintained at 37°C. The endothelium and adventitia were removed, and the resulting aorta was crushed. Complete DMEM containing 0.2% collagenase (DMEM containing 10% FBS, an ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to view more

Abstract

A coronary restenosis in a mammal can be prevented or treated by administering a pharmaceutical composition comprising an effective amount of catechin thereto.

Description

field of invention [0001] The present invention relates to the application of catechin for treating or preventing restenosis of coronary artery. Background of the invention [0002] Green tea contains 10%-15% tea tannin astringent. Tea tannins include polyphenols which are epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate (GCG), Catechin compounds represented by epicatechin (EC), gallocatechin-3-gallate (GCG), gallocatechin (GC) and catechin (C). [0003] The reported catechins have the property of inhibiting the activity of peroxy-ester compounds (Kinura et al., J.Jpn.Soc.Nutr.Food Sci., 37, 223-232 (1984)); Antioxidant activity of oil (Okuda, T. et al., Chem.Pharmacol.Bull., 31, 1625-1631 (1983)); antihypertensive activity; antifungal activity; antihyperglycemic activity; hypercholesterolemia inhibitory activity; antiulcer activity; and anticancer activity (Fukuyo, M. et al., J. Jpn. Soc. Nutr. Food Sci., 39, 495-500 (1986)). [0004] Per...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D311/62A61K31/35A61K31/353A61K36/18A61K36/82A61P9/10
CPCA61K31/35A61P9/10A61K36/82
Inventor 安熙悦曹明灿金英奎尹汝杓朴钟凡
Owner SAM A PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap